Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early‐onset Alzheimer's disease

Abstract Introduction People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. Methods Noradrenaline, adrenaline, and their metabolite 3‐methoxy‐4‐hydr...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Alain D. Dekker, Yannick Vermeiren, Maria Carmona‐Iragui, Bessy Benejam, Laura Videla, Ellen Gelpi, Tony Aerts, Debby Van Dam, Susana Fernández, Alberto Lleó, Sebastian Videla, Anne Sieben, Jean‐Jacques Martin, Netherlands Brain Bank, Rafael Blesa, Juan Fortea, Peter P. De Deyn
פורמט: Artigo
שפה:Inglês
יצא לאור: Wiley 2018-01-01
סדרה:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
נושאים:
Alzheimer's disease
Cerebrospinal fluid
Dementia
Dopamine
Down syndrome
Monoamines
גישה מקוונת:https://doi.org/10.1016/j.dadm.2017.11.001
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים